Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

December 20, 2018

Primary Completion Date

May 7, 2024

Study Completion Date

May 7, 2024

Conditions
Metastatic Colorectal CancerGastric CancerGastroesophageal Junction Adenocarcinoma
Interventions
DRUG

TEW-7197

"Vactosertib will be administered orally without regard to meals for 5 days per week (5D/W) at the same time in the morning (QD), at the same time in the morning and evening (BID) approximately 12 hours apart.~Pembrolizumab will be administered as a dose of 200 mg using a 30-minute IV infusion. Sites should make every effort to target infusion timing to be as close to 30 minutes as possible."

Trial Locations (5)

Unknown

National Cancer Center, Goyang

Seoul National University Bundang Hospital, Seongnam

Samsung Medical Center, Seoul

Yeonsei University Hospital, Seoul

05505

Asan Medical Center, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

MedPacto, Inc.

INDUSTRY

NCT03724851 - Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer | Biotech Hunter | Biotech Hunter